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Anemia is a commonly observed co-morbidity in heart failure (HF). The aim of the study was to assess prevalence, 
risk factors for, and effect of anemia on short- and long-term outcomes in HF. The study included 1,394 Caucasian 
patients hospitalized for HF, with known hemoglobin concentration on hospital admission, participating in 2 HF 
registries of the European Society of Cardiology (Pilot and Long-Term). Anemia was defined as hemoglobin 
concentration of <13 g/dl for men and <12 g/dl for women. Primary end points were (1) all-cause death at 1 year and 
(2) a composite of all-cause death and rehospitalization for HF at 1 year. Secondary end points included inter alia 
death during index hospitalization. In addition, we investigated the effect of changes in hemoglobin concentration 
during hospitalization on prognosis. Anemia occurred in 33% of patients. Predictors of anemia included older age, 
diabetes, greater New York Heart Association class at hospital admission and kidney disease. During 1-year follow-
up, 21% of anemic and 13% of nonanemic patients died (p <0.0001). Combined primary end point occurred in 45% 
of anemic and in 33% of nonanemic patients (p <0.0001). Anemia was strongly predictive of all the prespecified 
clinical end points in univariate analyses but not in multivariate analyses. Changes in hemoglobin concentration 
during hospitalization had no effect on 1-year outcomes. In conclusion, anemia was present in 1/3 of patients with 
HF. Mild-to-moderate anemia seems more a marker of older age, worse clinical condition, and a higher co-morbidity 
burden, rather than an independent risk factor in HF. 
 
 
 
 
 
  
Identification and prevention of risk factors for heart failure (HF) decompensation constitute the 
fundamentals of comprehensive care in HF.1, 2, 3 Although anemia is a commonly observed co-
morbidity in HF, associated with significantly worse prognosis, there is no certain explanation on how it 
affects mortality, provokes HF exacerbations, and influences the course of hospitalization.4, 5, 6, 7, 8, 9 
There are encouraging reports on the effectiveness of iron therapy in reducing HF symptoms; however, 
there are no favorable results in terms of mortality in HF.10, 11, 12, 13 Thus, clinical implications of 
anemia in HF remain to be established. The aim of this study was to evaluate the prevalence of anemia in 
patients hospitalized for HF, compare baseline characteristics and course of index hospitalization of 
anemic and nonanemic HF patients, and determine the impact of anemia on short- and long-term 
outcomes in HF. Additional objectives of the analysis were to assess risk factors for anemia in HF 
patients and to evaluate changes in hemoglobin concentration during hospitalization and their prognostic 
significance in HF. 
Methods 
The study is based on 2 prospective, multicenter, observational surveys of patients with HF, 
conducted by the European Society of Cardiology (ESC). The first, ESC-HF Pilot Survey, which has 
already been completed, was conducted from October 2009 to May 2010 in 136 European cardiology 
centers, including 29 centers from Poland.
14
 The second, ESC-HF Long-Term Registry, is a 3-phase 
study, conducted in 211 European cardiology centers, including 35 centers from Poland.
15
 In the ESC-HF 
Pilot Survey and during phase I of the ESC-HF Long-Term Registry (lasting from May 2011 to April 
2013), patients were enrolled on 1 specific day of the week for 12 consecutive months in each of the 
participating centers. In phase II and phase III (still on-going) of the ESC-HF Long-Term Registry, 
patients are enrolled during 5 days per trimester. The current analysis included Polish participants of the 
ESC-HF Pilot Survey and of phase I of the ESC-HF Long-Term Registry. 
 
The surveys included both ambulatory and hospitalized HF patients, who were aged over 18 years. 
There were no specific exclusion criteria. Local ethics committees approved the surveys in accordance 
with the regulations of each participating country. All patients were provided with detailed information on 
the registries and signed informed written consent. 
 
The current analysis included only patients admitted to hospital for new-onset or worsening HF, in 
whom data on hemoglobin concentration on hospital admission were available. 
 
Patients were divided into 2 groups (anemic and nonanemic) according to hemoglobin concentration 
on admission. Following the World Health Organization criteria, anemia was defined as hemoglobin 
concentration of <13 g/dl for men and <12 g/dl for women. Severe anemia was defined as hemoglobin 
level <9 g/dl. Anemic and nonanemic patients were compared with regard to baseline characteristics, 
course of index hospitalization, diagnostic tests results, implemented treatment, in-hospital outcomes 
(death during hospitalization, length of hospital stay, time in intensive cardiac care unit [ICCU]) and 1-
year outcomes (all-cause death and death or rehospitalization for decompensated HF). 
 
The primary end points were (1) all-cause death at 1 year and (2) a composite of all-cause death and 
hospital readmissions for decompensated HF at 1 year. Secondary end points included (1) death during 
index hospitalization, (2) hospital stay >7 days, (3) time in ICCU >3 days, and (4) a worse clinical status 
(New York Heart Association [NYHA] class III or IV) at hospital discharge. 
 
The main goal of the study was to determine whether anemia at hospital admission was predictive of 
the primary and the secondary end points in patients with HF. In addition, we assessed, whether changes 
in hemoglobin concentration during index hospitalization were related to 1-year outcomes (all-cause 
death and death or rehospitalization for decompensated HF). Increase and decrease in hemoglobin 
concentration were defined as changes of ≥1 g/dl during index hospitalization. Finally, we sought to 
identify risk factors for anemia at admission in hospitalized HF patients. 
  
Statistical analyses were performed using SPSS 22 (SPSS Statistics, Inc., Chicago, Illinois) and SAS 
9.2 (SAS Institute Inc., Cary, North Carolina) software. Normally distributed continuous variables were 
presented as mean value and SD, whereas for ordinal variables and nonnormally distributed continuous 
variables, median value and interquartile range were given. Significance of differences between the 2 
groups was determined by Fisher's exact test for categorical variables and the Mann-Whitney U test for 
continuous and ordinal variables. Cox proportional hazards regression model was used to identify 
predictors of the primary end points, as well as to assess association of hemoglobin changes during index 
hospitalization and 1-year outcomes. To determine the predictors of the remaining secondary end points, 
univariate and multivariate logistic regressions were performed. Multivariate analyses included all 
variables found to be statistically significant in univariate analyses, maintaining adequate events per 
predictor variable values.
16
 The list of all variables included in univariate analyses (both in Cox 
proportional hazards analyses and in logistic regression analyses) is provided in Supplementary Table S1. 
Kaplan-Meier curves were developed for both primary end points. For all tests, p value below 0.05 was 
considered significant. All tests were 2 tailed. 
Results 
Figure 1 shows the flow chart of patient selection for the present study. Finally, the study group 
included 1,394 Caucasian patients. Median hemoglobin concentration at hospital admission was 13.4 g/dl 
(interquartile range: 12.0 to 14.5 g/dl). Anemia at hospital admission was present in 466 of the 1,394 
patients (33%). Severe anemia was reported in 28 patients (2%). Comparison of clinical characteristics 
and course of index hospitalization of anemic and nonanemic patients is presented in Tables 1 and 2. 
 
 
 
Figure 1. Flow chart of patient enrollment in the current analysis. *included in the comparative analysis of anemic and nonanemic 
patients and in the analyses of in-hospital outcomes. **death or rehospitalization for heart failure. pts = patients. 
  
Table 1. Baseline characteristics, clinical, and laboratory status at hospital admission of anemic and nonanemic patients 
Variable Non-anemic (n=928) Anemic (n=466) P-value 
Baseline characteristics 
 Age (years) 67.6 (58.0-77.0) 73.0 (64.2-81.0) <0.0001 
 Men 599 (65%) 319 (69%) 0.15 
 Body mass index (kg/m2) 28.0 (25.0-31.3); 
n=885 
26.8 (24.4-30.8); 
n=432 
0.003 
 Current left ventricular ejection fraction (%) 36 (25-50); n=814 37 (25-50); n=398 0.45 
 Previous heart failure hospitalization 473/927 (51%) 288/464 (62%) <0.0001 
 Idiopathic dilated cardiomyopathy 133 (15%) 41 (9%) 0.003 
 Ischemic etiology of heart failure 513 (55%) 293 (63%) 0.01 
 Prior percutaneous coronary intervention or coronary artery bypass 
grafting 
296 (32%) 177/465 (38%) 0.02 
 Valve disease etiology of heart failure 109 (12%) 67 (14%) 0.17 
 Moderate or severe aortic stenosis 61/830 (7%) 39/403 (10%) 0.18 
 Moderate or severe aortic regurgitation 53/830 (6%) 46/403 (11%) 0.003 
 Moderate or severe mitral regurgitation 412/828 (50%) 210/404 (52%) 0.47 
 Moderate or severe tricuspid regurgitation 274/827 (33%) 181/404 (45%) <0.0001 
 Hypertension 629/926 (68%) 330 (71%) 0.30 
 History of atrial fibrillation 376/926 (41%) 232 (50%) 0.001 
 Peripheral artery disease 101/927 (11%) 77/465 (17%) 0.004 
 Diabetes 296 (32%) 198 (43%) <0.0001 
 Chronic kidney disease 161 (17%) 132/464 (28%) <0.0001 
 Chronic obstructive pulmonary disease 142 (15%) 119/464 (26%) <0.0001 
 Prior stroke or transient ischemic attack 95 (10%) 51/464 (11%) 0.71 
 3 or more non-cardiac comorbidities∗ 60 (7%) 54/464 (12%) 0.001 
 Current or former smoking 519/915 (57%) 251/455 (55%) 0.60 
 Alcohol usage 515/899 (57%) 236/448 (53%) 0.12 
Previous pharmacotherapy 
 Diuretic 598/912 (66%) 316/449 (70%) 0.09 
 Aldosterone antagonist 409/907 (45%) 197/450 (44%) 0.69 
 Angiotensin converting enzyme inhibitor 574/908 (63%) 275/449 (61%) 0.51 
 Angiotensin receptor blocker 87/906 (10%) 28/448 (6%) 0.04 
 β-blocker 677/908 (75%) 334/449 (74%) 0.95 
 Statin 490/910 (54%) 252/447 (56%) 0.39 
 Anticoagulant 270/911 (30%) 156/448 (35%) 0.054 
 Antiplatelet 476/909 (52%) 248/448 (55%) 0.33 
Clinical status at admission 
 Cardiogenic shock 22/890 (3%) 12/448 (3%) 0.86 
 Heart rate (b.p.m.) 80 (70-100); n=927 80 (70-100); n=464 0.75 
 Systolic blood pressure (mmHg) 130 (112-147); n=926 130 (110-140); n=465 0.17 
 NYHA class I 6/924 (1%) 4/463 (1%) 0.74 
 NYHA class II 249/924 (27%) 76/463 (16%) <0.0001 
 NYHA class III 425/924 (46%) 221/463 (48%) 0.57 
 NYHA class IV 244/924 (26%) 162/463 (35%) 0.001 
 Ventricular fibrillation or ventricular tachycardia as a cause of admission 87/925 (9%) 21 (5%) 0.001 
 Acute coronary syndrome as a cause of heart failure decompensation 184/926 (20%) 88/465 (19%) 0.72 
 Atrial fibrillation as a cause of heart failure decompensation 235/927 (25%) 115 (25%) 0.79 
 Infection as a cause of heart failure decompensation 85/924 (9%) 85 (18%) <0.0001 
Table 1. Baseline characteristics, clinical, and laboratory status at hospital admission of anemic and nonanemic patients 
Variable Non-anemic (n=928) Anemic (n=466) P-value 
Laboratory findings at admission 
 Hemoglobin (g/dl) 14.1 (13.4-15.0) 11.5 (10.5-12.1) <0.0001 
 Serum creatinine (mg/dl) 1.04 (0.89-1.29); 
n=908 
1.21 (0.99-1.64); 
n=462 
<0.0001 
 Estimated glomerular filtration rate (ml/min/1.73m2) 66.8 (52.3-86.3); 
n=908 
56.2 (40.3-75.8); 
n=462 
<0.0001 
 Serum sodium (mmol/l) 139 (137-141); n=925 138 (135-141); n=463 0.03 
    
 
Categorical data are presented as number of patients and percentages. Continuous variables are shown as a median and interquartile 
range. p Values are given for differences between the groups. Bolded text indicates p values <0.05. 
∗ Included diabetes, stroke or transient ischemic attack, peripheral artery disease, chronic obstructive pulmonary disease, and 
chronic kidney disease. 
 
Table 2. Clinical course of index hospitalization, in-hospital, and long-term outcomes of anemic and nonanemic patients 
Variable 
Non-anemic 
(n=928) 
Anemic 
(n=466) 
P-value 
Management during index hospitalization 
 Inotropic support 97/925 (11%) 73/464 (16%) 0.01 
 Intravenous diuretics 580/925 (63%) 357/464 (77%) <0.0001 
 Intravenous nitrates 116/925 (13%) 78/463 (17%) 0.03 
 Percutaneous coronary intervention / coronary artery bypass grafting during 
hospitalization 
127/925 (14%) 51/465 (11%) 0.15 
Status at discharge∗ 
 Heart rate (b.p.m.) 70 (65-80); n=900 70 (66-80); n=436 0.14 
 Systolic blood pressure (mmHg) 120 (110-130); 
n=906 
120 (105-130); 
n=441 
0.10 
 NYHA class I 60/909 (7%) 31/442 (7%) 0.82 
 NYHA class II 597/909 (66%) 242/442 (55%) <0.0001 
 NYHA class III 238/909 (26%) 162/442 (37%) <0.0001 
 NYHA class IV 14/909 (2%) 7/442 (2%) 1.00 
 Hemoglobin (g/dl) 13.8 (12.9-14.9); 
n=534 
11.4 (10.5-12.4); 
n=305 
<0.0001 
 Serum creatinine (mg/dl) 1.05 (0.90-1.30); 
n=639 
1.20 (0.97-1.67); 
n=334 
<0.0001 
 Serum sodium (mmol/l) 139 (136-141); 
n=683 
138 (136-141); 
n=357 
0.04 
Pharmacotherapy at discharge∗ 
 Diuretic 762/907 (84%) 391/443 (88%) 0.04 
 Aldosterone antagonist 618/906 (68%) 268/443 (61%) 0.01 
 Angiotensin converting enzyme inhibitor 700/908 (77%) 313/443 (71%) 0.01 
 Angiotensin receptor blocker 96/906 (11%) 34/442 (8%) 0.10 
 β-blocker 824/908 (91%) 390/443 (88%) 0.13 
 Statin 627/908 (69%) 301/443 (68%) 0.71 
Table 2. Clinical course of index hospitalization, in-hospital, and long-term outcomes of anemic and nonanemic patients 
Variable 
Non-anemic 
(n=928) 
Anemic 
(n=466) 
P-value 
 Anticoagulant 371/907 (41%) 205/443 (46%) 0.07 
 Antiplatelet 590/908 (65%) 292/443 (66%) 0.76 
In-hospital outcome 
 Hospitalization length (days) 7 (4-10) 8 (5-13) <0.0001 
 Time in Intensive Cardiac Care Unit (days) 0 (0-3); n=895 1 (0-6); n=447 <0.0001 
 Death during hospitalization 19 (2%) 23 (5%) 0.004 
1-year outcome† 
 Death 118/898 (13%) 95/443 (21%) <0.0001 
 Death or rehospitalization 266/803 (33%) 183/408 (45%) <0.0001 
    
 
Categorical data are presented as number of patients and percentages. Continuous variables are shown as a median and interquartile 
range. p Values are given for differences between the groups. Bolded text indicates p values <0.05. 
∗ In patients who survived to hospital discharge. 
† Including patients who died during index hospitalization. 
 
In the study group, independent predictors of anemia at hospital admission included older age, 
diabetes, greater NYHA class at admission, and kidney disease. 
 
Data on 1-year survival were available for 1,341 patients. A total of 213 patients (16%) died during 1-
year follow-up: 21% of the anemic and 13% of the nonanemic groups (Table 2). Kaplan-Meier curves for 
death at 1 year are presented in Figure 2. Predictors of death at 1 year are listed in Table 3. 
 
 
 
 
Figure 2. Kaplan-Meier curves for all-cause death at 1 year. 
  
Table 3. Univariate and multivariate analyses of predictors of death at 1 year 
Variable 
Univariate analysis  Multivariate analysis 
HR (95%CI) P-value  HR (95%CI) P-value 
      
Anemia at admission 1.74 (1.33-2.28) <0.0001  0.91 (0.72-1.44) 0.91 
Age (per 10 years) 1.04 (1.03-1.05) <0.0001  1.03 (1.02-1.05) <0.0001 
Current left ventricular ejection fraction (per 5%) 0.98 (0.97-0.99) 0.001  0.97 (0.96-0.98) <0.0001 
Peripheral artery disease 1.50 (1.05-2.15) 0.03  1.48 (0.98-2.25) 0.064 
Chronic kidney disease 1.87 (1.40-2.49) <0.0001  1.40 (0.98-2.00) 0.063 
NYHA class at admission (per 1 class) 2.33 (1.90-2.86) <0.0001  1.74 (1.32-2.29) <0.0001 
Serum sodium at admission (per 1 mmol/l) 0.91 (0.89-0.93) <0.0001  0.93 (0.90-0.96) <0.0001 
Angiotensin-converting-enzyme inhibitor or angiotensin 
receptor blocker at discharge 
0.32 (0.24-0.43) <0.0001  0.57 (0.38-0.83) 0.004 
β-blocker at discharge 0.30 (0.22-0.40) <0.0001  0.55 (0.36-0.84) 0.01 
      
 
Besides anemia, this table depicts only variables found to be predictive (or with a trend to be predictive) of the primary end point in 
the multivariate model. Other variables predictive of the primary end point in univariate analyses included body mass index, heart 
rate and systolic blood pressure at admission, history of atrial fibrillation, chronic obstructive pulmonary disease, diabetes and 
alcohol usage, infection as a cause of heart failure decompensation, moderate or severe mitral regurgitation, moderate or severe 
tricuspid regurgitation, serum creatinine at admission, statin, and antiplatelet treatment at discharge, all of them were also included 
in the multivariate model but did not prove independent predictors of death at 1 year. 
Bolded text indicates p values <0.05. 
CI = confidence interval; HR = hazard ratio; NYHA = New York Heart Association. 
Data on hospital readmissions for decompensated HF at 1 year were available for 1,211 patients. A 
total of 449 patients (37%) died or were readmitted for HF during 1-year follow-up: 45% of the anemic 
and 33% of the nonanemic groups (Table 2). Kaplan-Meier curves for death or rehospitalization for HF at 
1 year are presented in Figure 3. Predictors of death or rehospitalization for HF at 1 year are presented in 
Table 4. 
  
  
Figure 3. Kaplan-Meier curves for all-cause death or rehospitalization for heart failure at 1 year. 
Table 4. Univariate and multivariate analyses of predictors of death or rehospitalization for heart failure at 1 year 
Variable 
Univariate analysis  Multivariate analysis 
HR (95%CI) P-value  HR (95%CI) P-value 
      
Anemia at admission 1.50 (1.25-1.81) <0.0001  1.11 (0.89-1.40) 0.35 
Age (per 10 years) 1.01 (1.01-1.02) 0.001  1.01 (1.003-1.02) 0.04 
Current left ventricular ejection fraction (per 5%) 0.98 (0.98-0.99) <0.0001  0.98 (0.98-0.99) <0.0001 
History of heart failure hospitalization 1.40 (1.16-1.69) 0.001  1.25 (0.996-1.58) 0.053 
Diabetes 1.32 (1.10-1.60) 0.004  1.27 (1.02-1.58) 0.03 
Chronic kidney disease 1.60 (1.31-1.96) <0.0001  1.24 (0.97-1.59) 0.085 
Alcohol usage 0.73 (0.60-0.88) 0.001  0.78 (0.63-0.98) 0.03 
NYHA class at admission (per 1 class) 1.82 (1.59-2.08) <0.0001  1.40 (1.18-1.66) <0.0001 
Serum sodium at admission (per 1 mmol/l) 0.95 (0.93-0.96) <0.0001  0.97 (0.95-0.99) 0.002 
Angiotensin-converting-enzyme inhibitor or angiotensin 
receptor blocker at discharge 
0.48 (0.39-0.59) <0.0001  0.69 (0.53-0.90) 0.01 
β-blocker at discharge 0.52 (0.41-0.66) <0.0001  0.72 (0.52-0.98) 0.04 
      
 
Besides anemia, this table depicts only variables found to be predictive (or with a trend to be predictive) of the primary end point in 
the multivariate model. Other variables predictive of the primary end point in univariate analyses included heart rate and systolic 
blood pressure at admission, history of coronary artery disease, atrial fibrillation and chronic obstructive pulmonary disease, 
infection as a cause of heart failure decompensation, moderate or severe tricuspid regurgitation, serum creatinine at admission, 
statin, and antiplatelet treatment at discharge, all of them were also included in the multivariate model but did not prove independent 
predictors of death or rehospitalization for heart failure at 1 year. 
Bolded text indicates p values <0.05. 
CI = confidence interval; HR = hazard ratio; NYHA = New York Heart Association. 
  
Anemia was found to be strongly predictive of both primary end points only in univariate analyses, 
without statistical significance in multivariate analyses (Tables 3 and 4). 
 
With regard to the analysis of the secondary end points, in the study group of 1,394 patients, 42 
patients (3%) died during index hospitalization: 5% of the anemic and 2% of the nonanemic groups 
(Table 2). Predictors of death during hospitalization are listed in Table 5. 
Table 5. Univariate and multivariate analyses of predictors of death during hospitalization 
Variable 
Univariate analysis 
 
Multivariate analysis 
OR (95%CI) P-value 
 
OR (95%CI) P-value 
      
Anemia at admission 2.48 (1.34-4.61) 0.004  1.93 (0.86-4.35) 0.11 
Age (per 10 years) 1.04 (1.01-1.07) 0.01  1.04 (1.01-1.08) 0.02 
Current left ventricular ejection fraction (per 5%) 0.95 (0.92-0.98) 0.001  0.95 (0.92-0.99) 0.004 
Systolic blood pressure at admission (per 10 mmHg) 0.97 (0.96-0.98) <0.0001  0.99 (0.97-0.999) 0.04 
Heart rate at admission (per 10 b.p.m.) 1.02 (1.01-1.03) 0.003  1.02 (1.01-1.03) 0.01 
NYHA class at admission (per 1 class) 5.80 (3.07-10.94) <0.0001  3.41 (1.60-7.25) 0.001 
Serum sodium at admission (per 1 mmol/l) 0.88 (0.83-0.92) <0.0001  0.88 (0.83-0.94) <0.0001 
Serum creatinine at admission (per 1 mg/dl) 1.44 (1.13-1.85) 0.004  1.41 (1.04-1.91) 0.03 
      
 
Besides anemia, this table depicts only variables found to be predictive (or with a trend to be predictive) of the secondary end point 
in the multivariate model. Other variables predictive of the secondary end point in univariate analyses included acute coronary 
syndrome as a cause of heart failure decompensation, moderate or severe mitral regurgitation, and moderate or severe tricuspid 
regurgitation, all of them were also included in the multivariate model but did not prove independent predictors of death during 
hospitalization. 
Bolded text indicates p values <0.05. 
CI = confidence interval; NYHA = New York Heart Association; OR = odds ratio. 
Hospital stay >7 days was reported in 603 patients (43% of the study group), including 221 of the 466 
anemic patients (47%) and 382 of the 928 nonanemic patients (41%; p = 0.007). Time in ICCU >3 days 
was reported in 343 patients (26% of the 1,342 patients with data on ICCU stay), including 135 of 447 
anemic patients (30%) and 208 of 895 nonanemic patients (23%; p = 0.003). At hospital discharge, 
anemic patients more often were in NYHA class III or IV compared with nonanemic patients (p <0.0001; 
Table 2). 
 
Anemia was found to be predictive of all the aforementioned secondary end points only in univariate 
analyses, without statistical significance in multivariate analyses. 
 
Data on hemoglobin concentration at both hospital admission and hospital discharge were available 
for 871 patients. During index hospitalization, hemoglobin concentration increased (by ≥ 1 g/dl) in 132 
patients (15%), decreased (by ≥ 1 g/dl) in 183 patients (21%) and remained unchanged in 556 patients 
(64%). Changes in hemoglobin concentration during hospitalization had no effect on 1-year outcomes. 
  
Discussion 
Prevalence of anemia in patients with HF ranges from 5% to 70% in different studies, depending on 
anemia definition and patient characteristics.
5, 9
 In our study, prevalence of anemia (33%) was similar to 
the frequencies observed in a meta-analysis by Groenveld et al and in the Swedish HF Registry.
6, 17
 Lower 
prevalence of anemia (approximately 23% to 25%) was reported in 2 randomized clinical trials; however, 
recruited HF participants were significantly younger.
18, 19
 In most randomized clinical trials, severe 
anemia is an exclusion criterion, which makes it difficult to precisely assess this group of patients.
18, 20 
 
There is a variety of pathogenetic pathways of anemia development in HF
.7, 18, 21, 22, 23, 24
 In our 
analysis, independent risk factors for anemia included older age, diabetes, higher NYHA functional class 
at hospital admission, and kidney disease. In addition, anemic patients had significantly lower body mass 
index and were characterized by a higher cardiac and noncardiac co-morbidity burden, which might be 
partly explained by their older age. Due to decreased erythropoiesis, advanced chronic kidney disease 
leads to anemia.
22
 In advanced HF, anemia may also result from iron deficiency due to malabsorption, 
nutritional deficiencies, and impaired metabolism and from subclinical inflammation associated with 
bone marrow depression (anemia of chronic disorders).
7, 8, 18
 Furthermore, in hospitalized patients with 
severe HF, increased plasma volume and hemodilution may explain a higher prevalence of anemia.
7, 18
 
 
The EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with 
Tolvaptan) study and the IN-CHF Registry have demonstrated that anemic patients are less likely to 
receive guideline-recommended HF therapy, including β blockers and angiotensin-converting enzyme 
inhibitors.
21, 25
 In our study, at hospital discharge, angiotensin-converting enzyme inhibitors and 
aldosterone antagonists were significantly less often prescribed to anemic patients. This might have been 
due to worse renal function in anemic patients and might also add to worse 1-year outcomes observed in 
anemic patients. 
 
A meta-analysis of randomized clinical trials has shown that there is a strong association between 
anemia and adverse outcomes in HF.
6
 However, it is unclear that how anemia affects mortality and 
morbidity and whether it is indeed an independent risk factor or only a marker of worse clinical condition 
and a mediator of increased risk.
18, 20, 21 
 
The results of our study suggest that although anemia is a strong marker of unfavorable prognosis in 
HF, it is not an independent risk factor for adverse outcomes. This may be dictated by the fact that most 
predictors of anemia, such as older age, higher NYHA class at hospital admission, kidney disease, and 
diabetes overlaped with predictors of clinical endpoints. Likewise, the same risk factors for anemia were 
identified in the Swedish HF Registry, IN-CHF Registry (Italian Registry of Congestive Heart Failure), 
and Val-HeFT (Valsartan in Heart Failure Trial) trial.
17, 18, 25
 
 
In our study, mean age of the entire population (68 years) and the anemic cohort (73 years) was 
consistent with those of patients studied in the Swedish HF Registry and the EVEREST trial.
17, 21
 In 
contrast, in the randomized Val-HeFT trial and in the IN-CHF Registry, anemic HF patients were younger 
(66 and 67 years, respectively); in those patients, anemia was associated with increased morbidity and 
mortality.
17, 25
 In the Swedish HF Registry, the influence of anemia on mortality was significantly greater 
in younger patients and in those with more stable HF.
17
 In the ATTEND (Acute Decompensated Heart 
Failure Syndromes) registry, there was no association between anemia on hospital admission and all-
cause mortality in elderly patients.
9
 
 
Similarly, to the relation between anemia and 1-year outcomes in our study, in-hospital mortality rate 
was not influenced by anemia in multivariate analysis, despite a significant association in univariate 
analysis (with an odds ratio of almost 2.5). This indicates that although anemia itself may not be a direct 
cause of unfavorable in-hospital outcome, HF patients with concomitant anemia constitute a high-risk 
group and might therefore require more intensive monitoring. 
  
The results of our study imply that the previously observed relation between anemia and worse 
prognosis in HF is secondary to its association with older age, higher prevalence of cardiac and 
noncardiac comorbidities, and less frequent implementation of HF-modifying treatment. Reliability of our 
results is supported by the fact that other proved risk factors for in-hospital and long-term mortalities 
maintained statistical significance in multivariate analyses of the primary and the secondary end points.
1, 2, 
3, 26, 27, 28
 
 
Recently, studies on the impact of anemia correction in HF have been undertaken. In the IRON-HF 
(Randomized Trial to Assess the Effects of Iron Supplementation in Heart Failure Patients With Anemia) 
and FAIR-HF (Ferric carboxymaltose Assessment in patients with IRon deficiency and chronic Heart 
Failure) trials, HF patients with iron deficiency treated with intravenous iron experienced an improvement 
in quality of life, exercise tolerance, and NYHA functional class.
10, 11
 Moreover, in the CONFIRM-HF 
(Ferric CarboxymaltOse evaluatioN on perFormance in patients with IRon deficiency in coMbination 
with chronic Heart Failure) trial, intravenous iron therapy was associated with a significant reduction in 
rehospitalizations for worsening HF and with an insignificant reduction of mortality.
12
 However, it needs 
to be emphasized that inclusion criterion in these trials was iron deficiency, and not anemia itself, as the 
studies included both anemic and nonanemic patients. Iron deficiency may lead to anemia but also to 
muscle dysfunction without anemia.
1
 Thus, the beneficial effects of iron therapy in HF probably result 
from mechanisms other than merely correction of anemia. Furthermore, in a meta-analysis on 
erythropoiesis stimulating therapy (with darbepoetin or erythropoietin) for mild and moderate anemia in 
chronic HF, this treatment did not reduce all-cause mortality and rehospitalizations.
20
 This could also be a 
confirmation that anemia is merely a marker of a worse clinical status, including the presence of iron 
deficiency. Thus, it seems that alignment of hemoglobin level itself should not be a goal of HF treatment. 
 
The limitations of our study derive mainly from general drawbacks of registries, including 
incompleteness of data (e.g., data on 1-year survival and hospital readmissions). The scope of data 
collected in the registries was preestablished by their coordinators. Data on the underlying causes of 
anemia, parameters of iron deficiency, and information on possible iron supplementation were not 
available. 
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